公开(公告)号：US09751876B2

公开(公告)日：2017-09-05

申请号：US14511044

申请日：2014-10-09

Applicant: Novartis AG

Inventor： Ian Bruce ,  Sylvie Chamoin ,  Stephen Paul Collingwood ,  Pascal Furet ,  Vikki Furminger ,  Diana Janus ,  Sarah Lewis ,  Jon Christopher Loren ,  Valentina Molteni ,  Alex Michael Saunders ,  Duncan Shaw ,  Lilya Sviridenko ,  Christopher Thomson ,  Ryan West ,  Vince Yeh

IPC: C07D471/04 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/4745

CPC classification number: C07D471/04 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/5377 ,  A61K45/06

Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.

公开(公告)号：US10195181B2

公开(公告)日：2019-02-05

申请号：US15184730

申请日：2016-06-16

Applicant: Novartis AG

Inventor： Kamlesh Jagdis Bala ,  Andrew Brearley ,  James Dale ,  Anne-Marie Edwards ,  Mahbub Ahmed ,  David Porter ,  Robert Alexander Pulz ,  Lisa Ann Rooney ,  David Andrew Sandham ,  Duncan Shaw ,  Nichola Smith ,  Jessica Louise Taylor ,  Roger John Taylor ,  Thomas Josef Troxler ,  Joe Wrigglesworth

IPC: A61K31/422 ,  C07D413/14 ,  A61K31/4155 ,  C07D413/12

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US11672782B2

公开(公告)日：2023-06-13

申请号：US17089064

申请日：2020-11-04

Applicant: Novartis AG

Inventor： Kamlesh Jagdis Bala ,  Andrew Brearley ,  James Dale ,  Anne-Marie Edwards ,  Mahbub Ahmed ,  David Porter ,  Robert Alexander Pulz ,  Lisa Ann Rooney ,  David Andrew Sandham ,  Duncan Shaw ,  Nichola Smith ,  Jessica Louise Taylor ,  Roger John Taylor ,  Thomas Josef Troxler ,  Joe Wrigglesworth

IPC: A61K31/422 ,  A61K31/4155 ,  C07D413/12 ,  C07D413/14

CPC classification number: A61K31/422 ,  A61K31/4155 ,  C07D413/12 ,  C07D413/14 ,  A61K31/422 ,  A61K2300/00

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;




a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US11427586B2

公开(公告)日：2022-08-30

申请号：US17101510

申请日：2020-11-23

Applicant: NOVARTIS AG

Inventor： Kelly D. Boss ,  Yi Fan ,  Alec Nathanson Flyer ,  Declan Hardy ,  Zhihong Huang ,  Kathryn Taylor Linkens ,  Jon Christopher Loren ,  Fupeng Ma ,  Valentina Molteni ,  Duncan Shaw ,  Jeffrey Smith ,  Catherine Fooks Solovay

IPC: C07D471/10 ,  C07D413/14 ,  C07D491/107 ,  C07D413/06 ,  A61P27/04

Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I′), or pharmaceutical composition described herein.

公开(公告)号：US20220033407A1

公开(公告)日：2022-02-03

申请号：US17414672

申请日：2019-12-13

Applicant: NOVARTIS AG

Inventor： Mihai D. Azimioara ,  Bei Chen ,  Robert Epple ,  Declan Hardy ,  Ayako Honda ,  Philip Lam ,  Hasnain Ahmed Malik ,  Fabio Meier ,  Truc Ngoc Nguyen ,  Barun Okram ,  Sejal Patel ,  Rodrigo Rodriguez ,  Duncan Shaw ,  Yiping Shen ,  Baogen WU

IPC: C07D487/10 ,  C07D401/04 ,  C07D213/74 ,  C07D413/04 ,  C07D491/107 ,  A61K45/06

Abstract: The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

公开(公告)号：US09403810B2

公开(公告)日：2016-08-02

申请号：US14711684

申请日：2015-05-13

Applicant: Novartis AG

Inventor： Kamlesh Jagdis Bala ,  Andrew Brearley ,  James Dale ,  Anne-Marie Edwards ,  Mahbub Ahmed ,  David Porter ,  Robert Alexander Pulz ,  Lisa Ann Rooney ,  David Andrew Sandham ,  Duncan Shaw ,  Nichola Smith ,  Jessica Louise Taylor ,  Roger John Taylor ,  Thomas Josef Troxler ,  Joe Wrigglesworth

IPC: C07D413/12 ,  C07D413/14 ,  A61K31/4155 ,  A61K31/422

CPC classification number: A61K31/422 ,  A61K31/4155 ,  C07D413/12 ,  C07D413/14 ,  A61K2300/00

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐; 制备本发明化合物的方法及其治疗用途。 本发明还提供药理活性剂和药物组合物的组合。